Article
Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.
Advances in therapy - 1 Dec 2019
Fontana Robert J, Lens Sabela, McPherson Stuart, Elkhashab Magdy, Ankoma-Sey Victor, Bondin Mark, Dos Santos Ana Gabriela Pires, Xue Zhenyi, Trinh Roger, Porcalla Ariel, Zeuzem Stefan
Abstract excerpt
INTRODUCTION: The presence or absence of cirrhosis in patients with chronic hepatitis C virus (HCV) infection influences the type and duration of antiviral therapy. Non-invasive markers, like serum aspartate aminotransferase (AST) to platelet ratio index (APRI), may help identify appropriate HCV treatment-naive patients for 8-week treatment with the pangenotypic regimen of glecaprevir/pibrentasvir. METHODS: This...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.